ArticleScientific reports2025
Fermented seaweed extracts ameliorate diabetic nephropathy in streptozotocin-induced diabetic rats via PI3K/AKT/mTOR pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Polyphyllin II attenuates renal fibrosis in diabetic kidney disease partly through regulation of autophagy and PI3K/AKT/mTOR signaling.Frontiers in pharmacology · 2026Article
- Hydroxysafflor Yellow A improves diabetic nephropathy by inhibiting PI3K/AKT/mTOR pathway based on a multidimensional study.Frontiers in medicine · 2026Article
- Traditional Chinese medicine in the treatment of diabetic kidney disease: the mechanisms of signaling pathways regulations.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The seaweed Laminaria japonica possesses a wide range of nutritional and medicinal properties, such as antioxidant and hypoglycemic effects. Previous research has demonstrated that fermenting Laminaria japonica with S. cerevisiae and Lactobacillus enhances its bioactivities. In this study, fermented Laminaria japonica underwent ethanol extraction to recover bioactive compounds. The impact of fermented seaweed extracts (FSE) on renal injury in streptozotocin-induced diabetic nephropathy rats was examined. Through UHPLC-MS/MS analysis, 44 compounds were identified in the fermented seaweed extracts, with carbohydrates and organic acids being the main classes. Fermented seaweed extracts significantly reduced streptozotocin-induced hyperglycemia, improved renal function markers (BUN, SCr, and Umalb), and mitigated kidney morphological changes. Specifically, the FSE-H group exhibited a 49% reduction in fasting glucose levels compared to the model group. Additionally, fermented seaweed extracts treatment downregulated both the transcriptional and protein levels of PI3K, Akt, and mTOR, suggesting involvement of the PI3K/AKT/mTOR-regulated pathway. These findings suggest that fermented seaweed extracts have potential as a therapeutic agent or functional ingredient for the treatment of diabetic nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.